Feds: Pause Johnson & Johnson COVID Vaccine In NY, Elsewhere

0
40

NEW YORK – The Food and Drug Administration and the Centers for Disease Control and Prevention on Tuesday recommended the use of the Johnson & Johnson COVID-19 vaccine because of blood clotting concerns. The stagnation will affect many of New York’s vaccination sites.

The FDA announced on Twitter, “We are advising to take precautions to prevent the use of this vaccine.”

The Commissioner of Health Department of New York, Drs. Howard Zucker said in a prepared statement on Tuesday that the states would follow the recommendation of the CDC and FDA and immediately stop statewide use of the Johnson & Johnson vaccine.

He said that all appointments for the J&K vaccine on Tuesday at mass vaccination sites in New York State would be honored with the Pfx vaccine.

“As stated by the CDC and FDA, any adverse event related to the Johnson & Johnson vaccine appears to be ‘extremely rare’ and, ‘Those who have received the J&K vaccine who suffer from severe headaches, stomachaches, leg Develop pain, or lack of pain. Zucker stated that he should contact his healthcare provider within three weeks of vaccination.

“I am in constant contact with the federal government and we will update New Yorkers as more information becomes available,” he said.

The FDA and CDC are expected to resolve the problem during a 10 am media call. Watch live here:

The FDA reported that, as of Monday, more than 6.8 million doses of the New Jersey-based company’s vaccine have been administered in the US. The CDCA and FDA are reviewing six data that include rare and severe blood clots from US individuals. Are included. After receiving the vaccine.

The FDA stated, “At the moment, these adverse events appear to be extremely rare.” “Treatment of this specific type of blood clot is different from the treatment that can usually be administered.”

The CDC will convene a meeting of its Advisory Committee on Immunization Practices on Wednesday to further review these cases and assess their potential significance. The FDA will review that analysis because it also investigates these cases.

“We are recommending this stay until this process is complete,” the FDA said. “It is important to ensure that the health care provider community is aware of the potential of these adverse events and can plan because of the unique treatment required with this type of blood clotting.”

The CDC and FDA have also released a joint statement about the Johnson & Johnson COVID-19 vaccine, with Peter Marks as the director of the FDA’s Center for Biologics Evaluation and Research, Annie Schuchat, and the CDC’s head deputy director.

The statement stated that a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen with low levels of blood platelets (thrombocytopenia).

According to the statement, all six cases occurred in women between the ages of 18 and 48 and symptoms occurred six to 13 days after vaccination.

Stagnation is important, the statement said, “to ensure that the health care provider community is aware of the potential of these adverse events and planning appropriate accreditation and management because of the unique treatment required with this type of blood clotting. Could. “

“COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems seriously after COVID-19 vaccination,” the statement said.

Modern issued a statement saying it did not have the same results as the vaccine.

Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at the CDC and FDA and will respond to additional information and questions at a media briefing on Monday.

Recordings of that media call will be available on the FDA’s YouTube channel.

New Jersey Government. Phil Murphy sought to reassure people that the Johnson & Johnson vaccine is safe, despite a recent incident that led to the “contamination” of 15 million vaccines.

Human errors at a manufacturing plant that caused the company to throw out vaccines caused a huge drop in supply last week.

Written by Tom Davis / Patch with additional reporting by Michael Wotton / Patch.

LEAVE A REPLY

Please enter your comment!
Please enter your name here